Stopping or continuing hormone pill for low-grade uterine cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether it is better to stop a hormone tablet (an aromatase inhibitor) versus keep taking it in people with low-grade endometrial stromal sarcoma whose cancer is currently controlled. It may help find the safest way to maintain disease control while avoiding unnecessary treatment if stopping is possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your tumor has been confirmed as low-grade endometrial stromal sarcoma
- Your cancer is either advanced in the body or has spread, or it was found to have extended during surgery
- You have been taking an aromatase inhibitor (anastrozole, exemestane, or letrozole) long enough (about 24 months if no measurable cancer, or 36 months if measurable cancer)
- At the time of study entry, the cancer is controlled (no major growth—either stable or shrunk) on that hormone pill
- You can do daily activities at least fairly well (ECOG score 0–2), and you agree to join after informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether elacestrant, a drug that blocks estrogen, can help people with certain types of uterine sarcoma that have strong estrogen receptors. It may slow or stop cancer growth in tumors that rely on estrogen.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Hear when a new Low Grade Endometrial Stromal Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.